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Abstract
Background: Preventing the emergence of anti-malarial drug resistance is critical for the success
of current malaria elimination efforts. Prevention strategies have focused predominantly on
qualitative factors, such as choice of drugs, use of combinations and deployment of multiple first-
line treatments. The importance of anti-malarial treatment dosing has been underappreciated.
Treatment recommendations are often for the lowest doses that produce "satisfactory" results.
Methods:  The probability of de-novo resistant malaria parasites surviving and transmitting
depends on the relationship between their degree of resistance and the blood concentration
profiles of the anti-malarial drug to which they are exposed. The conditions required for the in-
vivo selection of de-novo emergent resistant malaria parasites were examined and relative
probabilities assessed.
Results:  Recrudescence is essential for the transmission of de-novo resistance. For rapidly
eliminated anti-malarials high-grade resistance can arise from a single drug exposure, but low-grade
resistance can arise only from repeated inadequate treatments. Resistance to artemisinins is,
therefore, unlikely to emerge with single drug exposures. Hyperparasitaemic patients are an
important source of de-novo anti-malarial drug resistance. Their parasite populations are larger,
their control of the infection insufficient, and their rates of recrudescence following anti-malarial
treatment are high. As use of substandard drugs, poor adherence, unusual pharmacokinetics, and
inadequate immune responses are host characteristics, likely to pertain to each recurrence of
infection, a small subgroup of patients provides the particular circumstances conducive to de-novo
resistance selection and transmission.
Conclusion: Current dosing recommendations provide a resistance selection opportunity in
those patients with low drug levels and high parasite burdens (often children or pregnant women).
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Patients with hyperparasitaemia who receive outpatient treatments provide the greatest risk of
selecting de-novo resistant parasites. This emphasizes the importance of ensuring that only quality-
assured anti-malarial combinations are used, that treatment doses are optimized on the basis of
pharmacodynamic and pharmacokinetic assessments in the target populations, and that patients
with heavy parasite burdens are identified and receive sufficient treatment to prevent
recrudescence.
Background
Resistance to anti-malarial drugs poses a major threat to
malaria control and elimination. Anti-malarial drug
resistance emerges de-novo when malaria parasites with
spontaneously arising mutations or gene duplications
conferring reduced drug susceptibility are selected by anti-
malarial drug concentrations sufficient to suppress the
growth of sensitive, but not the newly arisen resistant
mutant parasites [1-4]. For these new resistant parasites to
spread to other hosts, the resistance mechanism must not
affect their fitness greatly, so that the resistant parasites
can expand in numbers to generate gametocyte densities
sufficient for transmission to biting anopheline mosqui-
toes [5]. As the de-novo resistance event is probably inde-
pendent of the drug effect it can happen whenever there is
DNA replication. It could arise in the vector mosquito
(where meiosis occurs), during the pre-erythrocytic liver
stage development, or during the blood stage infection
[6]. There has been much debate and controversy over the
likely source of de-novo anti-malarial resistance and its
geographic origins. The numbers of malaria parasites cir-
culating in areas of high malaria transmission are consid-
erably greater than in areas of low and seasonal
transmission, and so early predictions were that resistance
would arise more frequently in these areas [7]. History
indicates the opposite. Resistance to the main anti-malar-
ials chloroquine, sulphadoxine-pyrimethamine, meflo-
quine, and artemisinin, has arisen in low transmission
areas and then spread [8]. South East Asia has been a con-
sistent epicentre of resistance. Resistant parasites originat-
ing there have spread to Africa. In contrast, the emergence
and spread of anti-malarial drug resistance seems to have
been slowest in areas of high stable transmission. The
principle reasons for this difference is the considerable
brake on resistance emergence and spread conferred by
host immunity, and the associated large transmission res-
ervoir provided by asymptomatic untreated individuals,
which dilutes the selective pressure provided by the anti-
malarial drugs. Mathematical modelling of anti-malarial
resistance has tended to focus on parasitological factors
and simplify host contributions to the emergence of resist-
ance. Here, the importance of anti-malarial dosing, and
the particular role that patients with heavy parasite bur-
dens play in generating anti-malarial drug resistance, and
the circumstances most conducive to its subsequent
spread are examined.
Intra-host malaria population dynamics
Heritable anti-malarial drug resistance could arise at any
nuclear division. Within host parasite numbers vary in the
course of a malaria infection over six to 12 orders of mag-
nitude. After sporozoites are inoculated by a feeding
female anopheline mosquito they find their way to the
liver within one hour. Each infects a hepatocyte. In
human malarias the actual numbers inoculated are not
known, but indirect studies suggest a skew distribution
with a median value of approximately 8-10 sporozoites
[3,4]. Multiplication within the entire human infection is
asexual with replication by mitosis. Within these few
infected liver cells the parasites divide repeatedly every
eight hours or so for approximately 16 serial sets of divi-
sions until each cell contains some 35,000 merozoites.
After approximately 5.5 days in Plasmodium falciparum
infections the infected liver cells burst (schizont rupture)
liberating the infectious merozoites into the blood
stream. The merozoites rapidly invade passing erythro-
cytes. This is the number of parasites that would be
exposed to anti-malarial drugs when a newly acquired
infection encounters residual anti-malarial drug levels
from a previous treatment, or during chemoprophylaxis.
For Plasmodium falciparum, Plasmodium vivax, and Plasmo-
dium ovale, each asexual cycle within the red cells lasts
approximately two days and multiplication initially is
usually reasonably efficient (20-50% efficiency). The aver-
age parasite multiplication factor (PMF) per generation in
non-immunes usually ranges between 5 and 25 with esti-
mated median values of 8 to 13 [9-11]. This results in
exponential population growth. Multiplication factors
drop abruptly soon after the patient becomes ill. Numer-
ous factors, not all of which are understood, contribute to
this abrupt reduction in PMF. These include activation of
non-specific host defence mechanisms, increased splenic
clearance function, inhibition of schizont development
by fever, and exhaustion of susceptible erythrocytes. Quo-
rum sensing in malaria parasites has not been well charac-
terized. Without anti-malarial treatment the intra-host
parasite population usually stabilizes and then eventually
declines [9-14]. Hyperparasitaemia and a fatal outcome
can be considered an unusual failure of these various host
and parasite control mechanisms. A parasite burden of 5
× 1011 parasites in an adult gives a parasitaemia of approx-
imately 1% (depending on parasite stage and synchronic-
ity of infection). This is not yet a lethal burden, but theMalaria Journal 2009, 8:253 http://www.malariajournal.com/content/8/1/253
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next multiplication step is critical to outcome. The patient
is teetering on the edge of a precipice as a PMF ≥ 5 will cre-
ate a potentially lethal sequestered biomass [15], whereas
a factor of one or less will almost guarantee recovery.
Effective anti-malarial treatment reduces multiplication
abruptly resulting in a rapid decline in parasite numbers.
This is a first order process, resulting in killing of a fixed
fraction of the parasite population each asexual cycle.
Fractional reductions in parasite numbers per asexual
cycle (parasite reduction ratios [PRR] which are the recip-
rocal of the PMF) are typically 1000, or with artemisinin
treatment as high as 10,000 [16].
Anti-malarial drug treatment limits transmissibility of the
infection as the sexual stages derive from the asexual
stages, which are killed by the drugs. Peak gametocyte
densities are therefore a function of peak asexual parasite
densities. Falciparum malaria differs from the other
human malarias in that gametocyte production is delayed
with respect to asexual parasite multiplication; peak
gametocytaemia occurs seven to10 days later [5,12,17]. As
a result effective treatment has a greater effect in reducing
the transmissibility of P. falciparum infections compared
with the other human malarias.
The relationship between the level of anti-malarial 
resistance and the probability of selecting resistance de-
novo
Drug resistance describes a right shift, and sometimes a
change in shape, of the concentration-effect relationship.
Evaluations of anti-malarial resistance have tended to
consider resistance as a binary (or sometimes ternary) var-
iable, whereas there is more commonly either a continu-
ous or multimodal distribution of susceptibility to any
drug. It is important to note that resistance is not equiva-
lent to treatment failure. Patients with fully sensitive par-
asites may fail treatment because of inadequate treatment
or pharmacokinetic factors, and patients with highly
resistant parasites may be cured because of the host's
immunity. The degree of resistance conferred by a genetic
event in malaria parasites is critically important both to
therapeutic response and to the probability of the resist-
ant parasites being selected. There is no selection of resist-
ance if the anti-malarial drug concentrations are high
enough to kill all the sensitive and all the resistant para-
sites, or too low to kill either. Thus, there is a window of
concentrations for any particular level of resistance that
provide a selection opportunity [18].
De-novo anti-malarial drug resistance is relevant at a pop-
ulation level only if it is transmitted to other people. This
requires that the resistant parasites expand in numbers
and produce sufficient gametocytes to infect an anophe-
line mosquito vector. If the resistance mechanism conveys
a small increment in resistance, as most mechanisms do
initially, then it offers limited opportunity for selection
i.e. provision of the difference in growth rates necessary
for the resistant sub-population to expand with respect to
the drug-sensitive sibling population [18]. On the other
hand, if the new genetic event confers a large reduction in
susceptibility in relation to therapeutic drug concentra-
tions, either upon a fully sensitive "wild-type" population
(e.g. the cytochrome b mutations which confer atovaquone
resistance), or upon an already resistant parasite popula-
tion (e.g. the Pfdhfr  I164L mutation, which invariably
occurs in parasites with other resistance mutations in this
gene), then de-novo selection occurs readily. This is
because "high-grade" resistance allows survival of para-
sites within the range of anti-malarial drug concentrations
that follow a standard dose ("therapeutic concentra-
tions"), whereas low grade resistance does not. This
increases the survival probabilities for resistant mutants
considerably, and it creates the conditions necessary for
selection. Thus the de-novo selection probability is
directly proportional to the level of resistance produced
by the genetic mutation or amplification. As a result, if
anti-malarial resistance progresses in a stepwise fashion
(such as antifol or sulpha resistance), and other factors are
equal, the rate of development of resistance would be
expected to accelerate. This is because with increasing lev-
els of resistance a greater proportion of de-novo resistant
parasites (and their progeny) can survive in the anti-
malarial drug concentrations that follow standard dosing.
Recrudescence of the infection is essential for transmis-
sion of de-novo resistant parasites. This is because the new
resistant parasites need to multiply from low numbers
(commonly only one) to reach a density sufficient to gen-
erate enough gametocytes to be taken up by a feeding
mosquito (a human body total of approximately one
hundred million parasites). At the same time the multipli-
cation of drug-sensitive sibling parasites must be sup-
pressed. For a two-day asexual cycle, at a PMF of 10, this
process takes 16 days.
Assessing levels of resistance
The level of resistance can be characterized in-vivo by the
PRR values of the resistant parasites in the anti-malarial
blood concentration range, which occurs during and fol-
lowing treatment. The PRR per cycle ranges from 0.1 (no
drug effect) to >10,000 with maximum effects from
artemisinin derivatives [16]. The lowest anti-malarial con-
centration resulting in the maximum possible PRR is the
minimum parasiticidal concentration (MPC), and the
concentration producing a growth rate of 1 is the mini-
mum inhibitory concentration (MIC). By definition
resistant parasites have higher MICs and MPCs than sen-
sitive parasites. Unfortunately, the relationship betweenMalaria Journal 2009, 8:253 http://www.malariajournal.com/content/8/1/253
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these in-vivo measures, and conventional in-vitro meas-
ures of susceptibility (IC50 or IC90) is not well character-
ized. This is because conventional tests measure
inhibition of growth (but not multiplication) under con-
stant drug exposure in conditions very different to that in-
vivo.
There is also often considerable variation between labora-
tories in in-vitro susceptibility assessments. In the early
stages of drug resistance, in which there is low grade resist-
ance, the concentrations of anti-malarial drug that imme-
diately follow treatment still exceed the MPC and it is only
after parasite densities have fallen below the level of detec-
tion that levels fall below the MIC. There is no prolonga-
tion of parasite clearance times. As resistance worsens (i.e.
the MPC rises) blood concentrations fall below the MPC
before parasitaemia falls below the level of detection.
Only then do parasite clearance times begin to lengthen.
Eventually, with further increases in resistance, parasite
reduction is insufficient to clear parasitaemia within seven
days (Figure 1).
The old WHO classification of resistance provides a con-
venient stratification for levels of resistance observed in
in-vivo drug trials, which can be translated readily into
PRR values.
R3: the highest level of resistance in which parasite
density falls by less than 75% in 48 hours (one cycle).
This results from a PRR of < 4/cycle.
R2: Parasitaemia falls by more than 75% in 48 hours,
but fails to clear in 7 days; this results from a PRR of
between 4 and 10/cycle, assuming an upper limit of
the total body parasite burden in clinical trials of 1012
parasites/person and a parasite detection limit of 108
parasites/person.
R1: recrudescence after seven days; assuming an upper
limit of the total body parasite burden in clinical trials
of 1012 parasites, this requires a PRR >10/cycle. This
can be further subdivided into R1a in which parasitae-
mia does not clear within 96 hours (PRR 10-100), and
those infections in which it does (PRR>100/cycle).
The corresponding growth rates per cycle are therefore;
R3; >0.25, R2; 0.1 to 0.25, R1a; 0.1 to 0.01, and R1b;
<0.01 (Figure 1). These are population averages but can be
translated into individual parasite probabilities of survival
and indicate that individual merozoite probabilities of
survival vary over almost five orders of magnitude. Thus
for a similar probability of mutation resistance is up to
10,000 times more likely to emerge for very high grade
resistance than for the lowest grade of resistance.
Implications
1. There is a selective window of anti-malarial drug
concentrations within which any given level of resist-
ance can emerge de-novo.
2. High grade resistance is selected more readily than
low grade resistance
3. If resistance develops in a series of equal incre-
ments, the rate of emergence increases.
Quantitating the risks of selecting and transmitting 
resistance
Malaria parasites enjoy a brief moment of diploidy in the
mosquito vector, but thereafter have a haploid existence.
Numbers vary from as few as the inoculation of a single
sporozoite to nearly 1013 blood stage asexual parasites in
a hyperparasitaemic adult. The emergence of drug resist-
ance in malaria parasites in relation to their site and stage
of development has been modelled recently [6]. These
probabilities are examined in Additional file 1.
Parasite multiplication efficiency and parasite burdens
For resistance arising de-novo during the blood stage
infection the probability distribution for numbers of
resistant parasites present in the body is a function of the
multiplication rate per asexual cycle, and the total number
Different levels of anti-malarial drug resistance provide differ- ent probabilities of individual parasite survival (inset) Figure 1
Different levels of anti-malarial drug resistance pro-
vide different probabilities of individual parasite sur-
vival (inset). The total numbers of parasites in an individual 
patient change with time. Treatment failure is defined as a 
failure to clear detectable parasites from the blood (R3, R2) 
or a subsequent recrudescence (R1). The former WHO clas-
sification of resistance translates into growth rates per cycle 
(PMF) as follows; R3; >0.25, R2; 0.1 to 0.25, R1a; 0.1 to 0.01, 
and R1b; <0.01. The inset shows the corresponding probabil-
ities of an individual parasite surviving one cycle if exposed to 
therapeutic drug concentrations.
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of parasites. PMF can range from negative values (with
self-cure, or following anti-malarial drug treatment) to
nearly 30 per asexual cycle. The absolute upper limit is set
by the number of merozoites per schizont. Parasite multi-
plication is always inefficient. A maximum (growth
phase) multiplication rate of 20 is very high and repre-
sents greater than 50% efficiency (E> 0.5), whereas a mul-
tiplication rate of two represents approximately 6%
efficiency (E = 0.06). Such a low multiplication rate prob-
ably could not be sustained for long enough to generate
high parasite burdens because of the induction of density
controlling non-specific and specific host-defence mecha-
nisms. For example it would take approximately one
month from hepatic schizogony for an infection with a
PMF of 2 to reach a detectable parasitaemia. Furthermore
with low multiplication factors, even if a resistance muta-
tion arose during mitosis, the resulting resistant mero-
zoite would have a correspondingly low probability of
invading and replicating successfully, whereas with highly
efficient multiplication these probabilities might exceed
50%. It is important to note that the multiplication of par-
asite populations which have already reached high densi-
ties is very unlikely to be efficient (and if they were, the
outcomes would probably be fatal, and therefore these
patients could not transmit de-novo resistance). This large
reduction in E at high densities has an important impact
on the survival of any de-novo resistant parasite emerging
in the multiplication step that generated the high densi-
ties irrespective of drug effects. For example if E falls ten
fold resulting in a drop in PMF from 10 in growth phase
to one at peak parasitaemia then the probability of there
being 10 (i.e. from the previous cycle) and one (current
cycle) potentially viable de-novo resistant intra-erythro-
cytic parasites becomes equal.
In non-immune patients multiplication factors for P. fal-
ciparum  in the growth phase of the infection can be
approximated to 10 per two-day asexual cycle [10,11],
representing 30-40% multiplication efficiency (E = 0.3 to
0.4; additional file; equation 3). Patients with acute
malaria present a range of parasite multiplication histo-
ries. Some will have been ill for many days with a rela-
tively low multiplication factors, significant red cell loss,
and consequent progressive anaemia. Others will have a
short history with highly efficient parasite multiplication
and often little or no anaemia (Figure 2). Hyperparasitae-
mia probably represents the more efficient multiplication
end of the spectrum, as low multiplication factors reflect
either host immunity or a resistant host phenotype and
are unlikely to be sustained for long enough to develop
hyperparasitaemia. This explains why hyperparasitaemic
non-immune patients are often not anaemic (as the
degree of anaemia is proportional to the duration and
severity of the infection). In higher transmission settings
the dynamics are more complex.
Doubling the multiplication rate doubles the efficiency of
replication and therefore doubles the probability that a
de-novo resistant parasite would survive. A rapidly
expanding infection is therefore more likely to generate
viable resistant parasites, and is also more likely to reach
high densities before multiplication factors fall (Figure
2A). But if hyperparasitaemia did arise in a slowly expand-
ing infection (Figure 2B), it would have arisen as a result
of a greater number of cell divisions, and have a corre-
spondingly greater probability of there being more than
one resistant mutant parasite present. This is outweighed
by the reduced survival probabilities that gave the low
multiplication rate in the first place.
Initial anti-malarial drug effects
Drug effects reduce the basal parasite multiplication rate.
Anti-malarial drugs act mainly at middle of the asexual
cycle, and have relatively less effects on formed schizonts.
Drug exposure occurs at peak parasitaemia. As the most
likely series of mitotic divisions to give rise to resistance is
the most recent (i.e. the mitotic events that gave rise to the
peak parasitaemia), the modal number of resistant mero-
zoites produced is one. But the survival probability of this
usually single parasite is low, as even if there was no treat-
ment, continued efficient multiplication is very unlikely.
For example a PMF of approximately one, which would be
quite likely in the absence of treatment at high parasite
densities, provides a probability of 7.5% of successful
progress of a resistant merozoite to the next asexual cycle.
This assumes an absolute maximum of 32 merozoites per
schizont, although it may be more realistic to assume this
Total numbers of malaria parasites in the body of two adults  (logarithmic scale; vertical axis) who develop similar hyper- parasitaemias are shown Figure 2
Total numbers of malaria parasites in the body of 
two adults (logarithmic scale; vertical axis) who 
develop similar hyperparasitaemias are shown. The 
days since acquiring the infection are shown on the horizon-
tal axis. The pre-erythrocytic development is approximately 
6 days. On the left A; the parasite multiplication factor (PMF) 
per asexual cycle is 25 representing highly efficient multiplica-
tion. On the right B; the multiplication factor is 6 per cycle, 
so it takes longer to develop hyperparasitaemia.
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maximum is 16 -thereby doubling the probabilities
(Additional file 1, equation 5). Thus, only one in 14 de-
novo events at this stage could progress one cycle even if
the level of resistance it conferred was so high that the
peak anti-malarial blood concentrations did not reach the
MICR. If the resistant parasite's progeny does survive one
cycle-at least one of the merozoites produced by the sub-
sequent "de-novo resistant" schizont 48 hours later must
also survive and invade successfully. This requires that the
anti-malarial blood concentrations 48 hours after starting
treatment must still not exceed MICR. For most resistance
mechanisms the initial levels of de-novo resistance are
insufficient for malaria parasites to survive therapeutic
blood concentrations of the anti-malarial drug. In other
words these de-novo resistant parasites are still killed by
"therapeutic concentrations". This is why incomplete
treatment is used in experimental models for selecting
resistance - and why incomplete treatment is so dangerous
in clinical practice. During the earlier growth phase of the
infection the chances of individual parasite survival are up
to ten times greater than at peak parasitaemia, but as over-
all parasite numbers are less, opportunities for resistance
to emerge are between 10 and 107 times lower. Even dur-
ing the most efficient growth phase only high levels of
resistance can survive therapeutic drug concentrations.
Peak anti-malarial drug concentrations are usually log-
normally distributed. If low drug concentrations occur
because of poor adherence, vomiting, malabsorption,
sub-standard drugs, or unusual pharmacokinetics, then
survival probabilities for resistant parasites increase. The
increase is non-linear reflecting the shape of the shifted
dose response curve and the shape of the probability dis-
tribution of drug concentrations. Resistance may be
selected if there is a sufficient difference in drug suscepti-
bilities between resistant and sensitive parasites (MICR
minus MICS) as discussed below.
Growth competition between resistant and sensitive parasites
De-novo resistant parasites can be considered in growth
competition with their drug sensitive, but otherwise iden-
tical, sibling parasites. This is particularly relevant to the
possible selection of artemisinin resistance as discussed
later. The width of the anti-malarial drug concentration
window of selection within which selection can take
place, is proportional to the degree of resistance [18]. If
anti-malarial plasma concentrations are below the win-
dow (underdosing, sub-standard drug, poor adherence,
vomiting, etc) then there will not be enough suppression
of the sensitive parasites, which will outgrow their resist-
ant siblings, and beat them in the race to reach transmis-
sible gametocyte densities. At a PMF of 10/cycle it takes
one resistant parasite over two weeks to generate enough
progeny to transmit. Recrudescence is necessary for selec-
tion (i.e. suppression of sensitive and expansion of resist-
ant parasites), and these recrudescent infections have a
greater per-infection probability of patent gametocytae-
mia than primary infections. Recrudescent infections are,
therefore, the source of resistance spread [19]. This is
examined in more detail below.
Before anti-malarial drug exposure multiplication rates of
the resistant parasite(s) will be lower (if fitness <1) than
or equal to the sensitive parasites. As discussed above if
resistance does arise de-novo then the modal number of
resistant mutant merozoites will be one, but there is a
smaller probability (determined by the multiplication
rate) that resistance arose earlier in the infection i.e. in an
earlier asexual generation or during liver stage develop-
ment (i.e. before treatment; Figure 3) and so generated
larger numbers of progeny. The probability that there is
more than one resistant parasite present at the time of first
drug exposure is obviously greater in patients with a high
parasitaemia. For resistance to spread the progeny of these
parasites must survive, and eventually expand in numbers
sufficient to generate enough gametocytes to transmit.
Usually resistance is associated with reduced fitness, and
thus reduced multiplication in comparison with drug sen-
sitive siblings. If this is the case, then the newly arisen
resistant mutants will comprise a smaller proportion of
the total parasite numbers at presentation than they did at
the time of their origin (Figure 3, right side). If there is
only one resistant parasite present (initially as a mero-
zoite) then the only anti-malarial concentrations that can
be selective are equal to or less than the minimum inhib-
itory concentration (MICR) [16]. This is because for the
single parasite's progeny to survive it must obviously have
a multiplication factor of ≥1 [18]. For larger numbers of
parasites arising from an earlier resistance event, anti-
malarial concentrations can exceed the MIC temporarily,
as long as they fall to ≤ MIC before elimination of all the
resistant parasites. This allows emergence of a lower grade
of resistance.
In summary, the rare instances when de-novo resistance
arises very early in the infection are particularly conducive
to resistance emergence for two reasons:
1. The total number of resistant parasites exposed to
the anti-malarial drug is greater, and the resistant pop-
ulation may, therefore, survive temporarily at concen-
trations above the MIC for the resistant parasites
(MICR).
2. The sensitive parasite population is correspondingly
reduced providing less growth competition.
For example, if anti-malarial drug resistance developed in
the mosquito and half the inoculated sporozoites wereMalaria Journal 2009, 8:253 http://www.malariajournal.com/content/8/1/253
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resistant, then if there were no fitness disadvantage, half
the blood stage parasites at any time before drug exposure
would be resistant [6].
Failure of host defence mechanisms and hyperparasitaemia
Immunity provides a powerful obstacle to the emergence
of resistance as immune responses kill parasites irrespec-
tive of their level of drug resistance. Anti-malarial drug
resistance historically has arisen predominantly in areas
of low malaria transmission where individuals have little
or no immunity. In endemic areas infants and young chil-
dren are relatively non-immune. Unless effective treat-
ment is readily available a greater proportion of infections
in non-immune patients reach high densities. Patients
with a high parasitaemia have, by definition, failed to
control their infection. The failure of host defence, which
allowed unrestricted parasite multiplication and conse-
quent hyperparasitaemia reflects several processes, which
facilitate the emergence of resistance. Evidently there is lit-
tle or no effective specific immunity against these particu-
lar parasites, even if there is against others, and non-
specific defences (splenic activation, innate immunity etc)
have been inadequate to control the parasite population
expansion. The higher recrudescence rates following anti-
malarial treatment of hyperparasitaemic infections results
from this failure of host defence, and that more treatment
is required to eliminate high burdens. It has been sug-
gested that the P. falciparum variant surface antigen spe-
cific antibody response would reduce considerably the
emergence of resistance. The volunteer experiments of
Martin and Arnold and others in which high level
pyrimethamine resistance in P. falciparum was selected
readily and repeatedly in non-immune volunteers, and
was more likely to emerge in those with a higher parasi-
taemia receiving a low dose, suggest this is not a major
impediment [20,21] (Table 1). The selection of
atovaquone resistance in one third of non-immune acute
falciparum malaria recipients also indicates the ease with
Total numbers of malaria parasites in the bodies of two adults (logarithmic scale; vertical axis) with similar rapidly expanding  infections who develop hyperparasitaemia (>5% parasitaemia) are shown against time since their infecting mosquito bites on  the horizontal axis Figure 3
Total numbers of malaria parasites in the bodies of two adults (logarithmic scale; vertical axis) with similar 
rapidly expanding infections who develop hyperparasitaemia (>5% parasitaemia) are shown against time since 
their infecting mosquito bites on the horizontal axis. The horizontal dotted line is the pyrogenic density (the density 
threshold for fever). The most likely mitotic division to give rise to de-novo resistance is the one immediately preceding peak 
parasitaemia. The most likely (i.e. modal) number of resistant parasites present therefore is one. There are correspondingly 
lower probabilities of there being much larger numbers of de-novo resistant parasites. The inset triangles represent the much 
rarer situation of earlier de-novo appearance of resistant mutants and the corresponding greater numbers of resistant para-
sites that would occur at presentation with hyperparasitaemia. In the example on the left the fitness and thus multiplication fac-
tor of the mutant parasites is unaffected by the resistance mechanism, whereas on the right their fitness and thus multiplication 
is reduced relative to their drug sensitive siblings.Malaria Journal 2009, 8:253 http://www.malariajournal.com/content/8/1/253
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which high-level resistance can emerge under drug selec-
tion in-vivo in a single passage [22]. The amplification in
the  Pfmdr1  gene, which causes mefloquine resistance,
occurs very frequently and emerges at an estimated fre-
quency of 1 in 108 mitotic divisions. It, therefore, devel-
ops frequently within an infection [23,24] (Figure 4).
Rapid selection of Pfmdr1 amplification is balanced by the
considerable fitness cost, so resistance is lost rapidly when
drug selective pressure is lifted.
Critical role of treatment failure in the genesis and transmission of 
resistance
Treatment failure leading to recrudescence is required in
nearly all cases for the transmission of de-novo resistance.
Any gametocytes transmitted from the acute illness epi-
sode from which the new resistant parasites arose (the pri-
mary infection) will derive from the much larger pool of
sensitive asexual parasites - except for the very rare event
when resistance emerged very early in the infection [5,25].
The primary infection gametocytes are, therefore, very
unlikely to contain any de-novo resistant mutants. For
example, if it is assumed arbitrarily that at least 10% of the
gametocytes must carry the new resistance mutation for
resistance to be transmitted [18], then with a parasite mul-
tiplication factor of 10, at least 10% of the parasites
emerging from the liver must carry the resistance mecha-
nism for transmission of resistance to occur from the pri-
mary infection. This leads to an important conclusion.
Transmission of de-novo resistance from the primary
infection cannot occur unless the resistance mechanism
arose in the liver stages.
Except in those very rare cases [6], which are approxi-
mately one million times less frequent than emergence
during the blood stage of a hyperparasitaemic infection,
the gametocytes, which transmit resistance, will arise from
the subsequent recrudescent infection. This requires sup-
pression of the sensitive parasites by drug treatment so
that only the resistant parasites can multiply and produce
the gametocytes in the recrudescent infection [25]. This is
an important bottleneck [6]. It is also evident that if
malaria parasites have already acquired high-grade resist-
ance resulting in early treatment failures -further selection
does not occur, so emergence of an even higher grade of
resistance in this context is not possible. For example, the
reason that P. vivax has not acquired an mutation anala-
gous to the Pfdhfr I164L mutation in P. falciparum (confer-
ring high grade antifol resistance) in South-East Asia may
be because the other Pvdhfr and Pvdhps mutations it has
developed there provide such high grade resistance to sul-
phadoxine-pyrimethamine, that further selection is
unlikely [26].
As described above the risks of treatment failure increase
with increasing pre-treatment parasite counts [27-31]. For
example on the north-western border of Thailand failure
rates with the three-day regimen of artesunate and meflo-
quine approximate 5%, but if the patient has >4% parasi-
taemia the failure rate approximates 30% [32]. Multiple
treatments may be required for the selection of resistance,
as is often the case in animal models, and so the much
higher rate of treatment failure with hyperparasitaemia,
and the higher rate of further treatment failure in recru-
descent infections conspire to create a scenario conducive
to selection. This scenario is more likely in low transmis-
sion settings where the immune response to malaria is not
primed, and multiple recrudescences commonly follow a
first recrudescence.
Asymptomatic parasitaemia
In malaria endemic areas, most people are infected with
malaria parasites most of the time, and many adults and
older children harbour a detectable parasitaemia for long
periods. These malaria parasites survive by evading the
immune response through antigenic variation and com-
peting successfully with other malaria parasites. These
infections intermittently produce transmissible densities
of gametocytes. Plasmodium falciparum asexual parasite
densities up to 10,000/uL can be asymptomatic. As indi-
viduals with asymptomatic parasitaemia may take anti-
malarial treatments for fevers (unrelated to malaria) they
do provide a resistance selection opportunity. Three fac-
tors reduce the probabilities of selection in asymptomatic
parasitaemia compared to that in symptomatic infections:
1. The effectiveness of the immune response that controlled
parasite densities below pyrogenic levels.
This prevents emergence from the main parasite pop-
ulation and requires the de-novo resistant parasite to
Approximate per-parasite probabilities of de-novo emer- gence of viable and transmissible resistant parasites in clinical  infections Figure 4
Approximate per-parasite probabilities of de-novo 
emergence of viable and transmissible resistant para-
sites in clinical infections. Mefloquine resistance results 
from Pfmdr amplification, pyrimethamine resistance from 
mutations in Pfdhfr, atovaquone resistance from mutations in 
Pfcyt b, and resistance to chloroquine from mutations in 
PfCRT.
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derive from a new antigenically variant and poorly rec-
ognized sub-population if the high growth rates neces-
sary to sustain low-grade resistance, and produce
sufficient gametocyte densities are to occur. The effects
of any fitness disadvantage are amplified at low overall
parasite growth rates.
2.  The low parasite density, and thus low number of
mitoses.
In a symptomatic infection anti-malarial treatment is
sought and taken exposing between 107  and 1013
malaria parasites to the drugs used. In an asympto-
matic infection parasite numbers are below the pyro-
genic density. If anti-malarial treatment is taken for
another incidental febrile infection it exposes between
104 and 1010 malaria parasites to the drugs used. The
asymptomatic infection, therefore, presents a much
lower probability of large numbers of de-novo resist-
ant parasites being present because total parasite num-
bers are usually orders of magnitude lower, and also
because growth of the resistant sub-population is
required to generate transmissible gametocyte densi-
ties.
3. Growth kinetics.
In contrast to a symptomatic malaria infection, which
has expanded rapidly to produce pyrogenic densities
of malaria parasites in the blood, and is then treated,
an asymptomatic infection is much less likely to be in
growth phase. Each asymptomatic infection parasite
population is in one of three phases (growth, quasi-
steady state, or elimination), whereas all symptomatic
infections have just been or are in growth phase. There
is insufficient information on the kinetic properties of
these phases in asymptomatic infections, but it is obvi-
ous that each individual parasite inoculation cannot
individually reach detectable parasite densities and
then persist otherwise everyone living in endemic
areas would have high density superinfections. The
most likely scenario is a series of superimposed waves
of parasitaemia with different amplitudes and fre-
quencies, but overall cumulative densities controlled
below pyrogenic levels (<10,000/uL) [33]. This con-
trol is a complex process but comprises, in part,
immune responses which will be directed equally at
sensitive and resistant parasites.
The processes which suppress expansion of the parasite
population are also likely to control multiplication of any
drug resistant mutants. Thus, the survival probability of
any newly formed resistant parasites is greatest during the
growth phase before immune control intervenes. The
lower the overall multiplication rate the lower is the prob-
ability of resistant parasites reaching transmissible densi-
ties, both because of immune control and the relatively
greater effects of any fitness disadvantage in competitive
multiplication.
Implications
1. Resistance is more likely to arise with high parasite
growth rates and high parasite burdens.
2. There is a complex trade-off in the probabilities of a
de-novo resistant parasite surviving between multipli-
cation efficiencies, parasite numbers, drug concentra-
tions and drug effects.
3. In nearly all circumstances, recrudescences, and in
most cases, multiple recrudescences are required for
the de-novo selection of resistance.
4. Once high-level resistance is established, even
higher levels cannot be selected.
5. Inadvertent anti-malarial treatment of an asympto-
matic parasitaemia is an unlikely source of de-novo
resistance.
Table 1: The rapid selection of pyrimethamine resistance in-vivo; recrudescence proportions in volunteers with falciparum malaria 
treated with pyrimethamine; from Martin and Arnold 1968 (21).
Pyrimethamine dose (mg) Highest observed parasite count/uL
<1000 1000 to 20,000 20,000 to 100,000 100,000 to 200,000 >200,000
12.5 2/5 1/1
25 0/10 5/5
50 2/2
100 0/1 0/1 0/1 1/1
150 0/1
Volunteers were given the Ugandan strain of P. falciparum by intravenous injection and treated with a single dose of pyrimethamine. All 
recrudescences occurred within 21 days. Recrudescent infections were highly resistant to treatment with 150 mg of pyrimethamine. The parasites 
were obtained from a child in Kampala in 1965. Pyrimethamine had been used extensively over the previous ten years, but not apparently in the 
area where this child originated from. Nevertheless the parasites may already have had some degree of resistance (i.e. resistance mutations in 
Pfdhfr).Malaria Journal 2009, 8:253 http://www.malariajournal.com/content/8/1/253
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Pharmacokinetic properties of relevance to de-novo 
selection
For resistance to spread, anti-malarial drug exposure must
be sufficient to suppress the growth of sensitive parasites
so that they comprise <90% of the total at the time of
recrudescence. This requires that the treatment provides a
sufficient differential effect [18]. High-level resistance
confers a large differential between the inhibitory effects
on sensitive parasites and the resistant sub-population,
and so, once de-novo high grade resistance has emerged,
it is more likely to survive (e.g. atovaquone resistance)
[22]. If not all the drug sensitive sibling parasites are elim-
inated and some survive then they will compete with the
newly arisen resistant parasites. Competition from drug-
sensitive siblings is particularly important for rapidly
eliminated drugs. Slowly eliminated drugs provide two or
more successive asexual cycles of differential growth sup-
pression (i.e. selection). Each cycle during which there is
some suppression of sensitive parasite growth increases
the difference between the newly emergent resistant and
the sibling sensitive parasites and thus the chances of
selection and ultimately transmission. This explains why,
under some circumstances, resistance emerges more read-
ily to slowly eliminated drugs [34], although slow elimi-
nation is of much greater relevance to the spread of
resistance as it provides a selective filter for resistant para-
sites acquired from elsewhere. As resistance is usually
associated with a fitness disadvantage in competitive
growth, it may be necessary to eliminate all the sensitive
parasites for the resistant mutants to survive.
The relationship between terminal elimination half-life of
the anti-malarial drug and opportunities for resistance
selection from infections newly acquired following drug
administration has been analysed in terms of a "window
of selection" [18]. The window was defined as the period
of time (containing a gradient of drug concentrations)
during which resistant parasites had the opportunity to
multiply and comprise ≥10% of gametocytes. The mathe-
matical details are given in Additional file 2. A similar
approach can be taken to initial anti-malarial drug con-
centrations in that there is a window of concentrations
within which selection of a particular level of resistance
can take place (Figure 5). The upper limit of the window
is defined by the plasma concentration of drug which will
kill both sensitive and resistant parasites. These have been
defined in terms of probabilities, which decline asymptot-
ically so the limit can be set at an arbitrary level (such as
less than 1% probability of survival). The lower limit is
defined by the plasma concentration at which the inhibi-
tion of sibling sensitive parasites' growth is insufficient to
prevent their progeny comprising ≥ 90% of the gameto-
cytes. Thus, there are a series of windows for different
numbers of de-novo resistant parasites. The width of the
window is determined by the degree of resistance i.e. the
difference in drug susceptibility between the de-novo
resistant mutant(s) and the remainder of the more sensi-
tive parasites. The majority parasites may already be par-
tially resistant, such as the stepwise acquisition of antifol
or sulpha resistance. This narrows the window. Resistance
arising in an earlier generation resulting in large numbers
of resistant parasites before drug exposure widens the win-
dow. If the de-novo resistance mechanism confers a large
decrease in drug susceptibility then the window is wide,
and may involve therapeutic concentrations of the drug
(e.g. e.g Pfdhfr 164 mutation; high-grade pyrimethamine
resistance) or narrow such that only sub-therapeutic con-
centrations can select (e.g Pfdhfr 108 mutation; low-grade
pyrimethamine resistance). Anti-malarial drug plasma
concentration profiles vary considerably between
patients. The closer anti-malarial drug concentrations are
to the range giving sub-maximal effects in all patients
(with sensitive parasites), the higher is the probability that
some patients have sub-therapeutic levels and so there is
a greater opportunity for selection in the narrow window
The anti-malarial concentration window of selection [18] Figure 5
The anti-malarial concentration window of selection 
[18]. The drug concentrations (solid lines) following two 
doses which define the concentration limits of the window of 
selection are shown for patients with low parasitaemias (108/
body). Total parasites within the body are depicted by dotted 
and dashed lines. The window opens when following the 
higher dose (blue) sensitive parasites (blue dotted line) are 
eliminated but de-novo resistant parasites (blue dashed line) 
can survive, and successful selection of resistance can take 
place. Following the lower dose the sensitive parasites can 
still survive (red dotted line) and later grow to outnumber 
the drug resistant parasites (blue dashed line) by >9:1, so 
there is no longer an opportunity for preferential survival of 
the resistant parasites and thus selection. The window 
closes. Concentrations between these two boundaries (the 
"window of selection") are selective.Malaria Journal 2009, 8:253 http://www.malariajournal.com/content/8/1/253
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of selection for low-grade resistance. This happens with
systematic underdosing (e.g. sulphadoxine-pyrimeth-
amine treatment regimens in children). It is a strong argu-
ment for recommending dose regimens which guarantee
maximum effects in nearly all patients infected with sen-
sitive parasites. These regimens will provide a greater
safety margin (in terms of efficacy) and thereby reduce the
selection opportunities for low-grade resistance. The con-
cept of mutation prevention in bacterial infections
through dose optimisation is now well established [35].
Similar arguments apply to anti-malarials. If low-grade
resistance is a necessary stepping-stone to higher levels of
resistance, then dose optimization [36] together with the
use of combination treatments, provide the best opportu-
nity to prevent the emergence of resistance.
The pharmacokinetic properties of anti-malarial drugs
vary considerably between individuals. At the extreme end
of the distribution lie patients with very low anti-malarial
drug concentrations despite having taken and retained a
full treatment dose. These patients are obviously more
likely to fail treatment, and they are also more likely to fail
again when retreated, as they will probably have low drug
levels again.
Implications
To prevent the emergence of resistance dose regimens
should aim to provide therapeutic concentrations in
nearly all patients. Current anti-malarial dose regimens
tend to be too low.
Characteristics associated with hyperparasitaemia of 
relevance to resistance
Parasite burdens
A high parasitaemia reflects a large sequestered parasite
burden in falciparum malaria, and carries a worse progno-
sis [37]. By definition, patients with hyperparasitaemia
represent the upper end of a frequency distribution of par-
asitaemia and so have more parasites in their blood than
the majority of patients with malaria. If hyperparasitae-
mia is defined as >5% parasitaemia, then the number of
blood stage parasites in the patient ranges between
approximately 5 × 1010 and 1013 depending on body size
and red cell count. Higher parasite burdens are impossi-
ble. Patients with uncomplicated malaria generally
present with malaria at total body burdens between 5 ×
106 and 1010 parasites depending again on body size, and
red cell count. Geometric mean parasite densities in drug
trials of uncomplicated malaria range typically from 1000
to 20,000/uL blood. Parasite burdens in hyperparasitae-
mia, and the total number of cell divisions per infection,
are therefore 10 to 10,000 times greater than in uncompli-
cated malaria. Thus, in terms of numbers of malaria para-
sites one hyperparasitaemic patient is equivalent to
between 10 and 10,000 patients with symptomatic but
otherwise uncomplicated malaria [3]. Thus, the number
of mitoses at which resistance could have arisen is up to
four orders of magnitude greater than in uncomplicated
malaria and up to eight orders of magnitude greater than
in parasites newly emergent from the liver stage develop-
ment. Hyperparasitaemic patients also offer greater selec-
tion possibilities after the first drug exposed cycle as there
are still up to 1010 parasites present two days after starting
treatment. Although selection probabilities are much
lower (by a fraction of 1/PRR) in the second cycle (two
days later) the drug levels may also be lower, and may
now be within the window of selection (Figure 5). This is
why hyperparasitaemic patients need longer courses of
treatment with rapidly eliminated drugs.
Failure of host-defence
There is great variability in the severity of malaria infec-
tions. Even non-immune subjects infected with the same
strain of parasite (as in the malariatherapy of neurosyph-
ilis or in volunteer studies) varied considerably in the
severity of infection that ensued [9-14]. Parasite clearance
rates vary considerably between individuals infected with
the same parasites and receiving similar anti-malarial
treatments. The evolution of the human genome in tropi-
cal countries has been molded by the selective pressure of
malaria. Hyperparasitaemia may, therefore, represent an
unfortunate host-parasite combination in which unre-
stricted parasite growth is favoured. The development of
hyperparasitaemia represents a failure of host-defence,
both of the non-specific host-defence processes that nor-
mally limit parasite expansion and also the parasite spe-
cific immune responses that control parasitaemia in
endemic areas. This indicates that an important obstacle
to the emergence of resistance is lacking for the particular
parasites (usually of a single dominant clone) causing the
high parasitaemia.
Increased risk of recrudescence
Patients with hyperparasitaemia are invariably ill and,
therefore, have a higher probability of being treated than
other infections, and they are at considerably greater risk
of failing treatment [27-31]. There are several reasons for
this:
i) there are more parasites to eliminate and anti-malar-
ial drug levels may fall below the minimum inhibitory
concentration before the infection is extinguished
(Figure 6).
ii) the patient is more ill, even if they do not yet have
signs of severe malaria, and, therefore, they are more
likely to vomit or malabsorb the anti-malarial treat-
ment, thereby creating lower potentially selective
blood concentrations. This may be particularly impor-
tant, and is an argument for using an alternative routeMalaria Journal 2009, 8:253 http://www.malariajournal.com/content/8/1/253
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of drug administration, such as pre-referral rectal
artesunate [38].
iii) hyperparasitaemic patients have by their nature
"declared themselves" unable to control this particular
infection.
Treatment failure means that retreatment is likely and
provides a second round of selection, so that if the new
resistant parasites are still in a minority (and contribute
less than 10% of the gametocytes at this stage), they now
have a second opportunity for selection, and have consid-
erable parasite numbers present. This provides a greater
chance of the resistant sub-population surviving "thera-
peutic concentrations" than in the original infection. Mul-
tiple recrudescences, therefore, provide a means of
enrichment of resistant phenotypes.
Implications
Hyperparasitaemic patients are an important source of
de-novo resistance because of the larger numbers of
parasites present, because the factors that led to these
unusually heavy parasite burdens may impair the kill-
ing of de-novo resistant parasites, and because they
have an increased risk of a subsequent recrudescent
infection. Resistance is more likely to arise with high
growth rates and high parasite burdens.
Likely scenarios
For most resistance mechanisms, the initial level of resist-
ance conferred is low, but with continued selection, the
level tends to increase as further mutations are selected.
The time scale is months to years. These new mutants can
be resistance conferring, or compensatory mutations,
which increase the fitness of resistant parasites. Selection
of resistance in animal models is usually best achieved by
giving a sub-curative dose, waiting for the parasite num-
bers to recover, and then repeating the dose [1,39-41].
This process may need to be repeated several times. This
same process happens in clinical practice when an indi-
vidual patient with hyperparasitaemia receives an inade-
quate single dose of anti-malarial, or vomits or
malabsorbs the drug, and the full treatment course is not
then received. These patients' infections are very likely to
recrudesce. Some patients have unusual anti-malarial
pharmacokinetics with expanded volumes of distribution
and/or high drug clearance resulting in low blood concen-
trations. These are host properties and so these patients
would be expected to have the same abnormalities on
retreatment. This is a particular problem when dose regi-
mens are relatively low (Table 2). It is worth noting that
combination drugs still provide some protection against
resistance in these scenarios [42].
Parasitaemia profiles in a recrudescent infection Figure 6
Parasitaemia profiles in a recrudescent infection. 
Patients with hyperparasitaemia are at greater risk of subse-
quent recrudescence even with fully sensitive parasites than 
patients with lower parasite densities. Each recrudescence 
provides an opportunity for enrichment (i.e. selection) of any 
resistant parasites formed. The total number of parasites in 
the body are shown on the lower vertical axis, drug concen-
trations of a slowly eliminated anti-malarial are shown in the 
upper panel. MIC: minimum inhibitory concentration.
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Table 2: Drugs for which currently recommended anti-malarial regimens maybe inadequate in important patient groups.
Drug Dose Patient group Comment
Dihydroartemisinin-
piperaquine
2.5/20 mg/kg/day for 3 days All The current adult DHA dose of 120 mg may be 
too low. The piperaquine dose may be too low in 
children
Sulphadoxine -pyrimethamine 1.25/25 mg/kg Children, pregnant women Higher doses have not been evaluated
Atovaquone-proguanil 8/20 mg/kg for 3 days Pregnant women Higher doses have not been evaluated
Artemether-lumefantrine 1.5/9 mg/kg for 3 days with fat Pregnant women
Hyperparasitaemic patients
Lumefantrine absorption is dose limited. Longer 
courses have not been evaluated in pregnancy
Artesunate Oral 2 mg/kg/day 7 days
2.4 mg/kg i.v.
Pregnant women Higher doses have not been evaluated in 
pregnancy
Artemether Oral 2 mg/kg/day 7 days
3.2 mg/kg i.m.
Pregnant women Higher doses have not been evaluated in 
pregnancy
The efficacy of three day artemisinin-combination regimens in hyperparasitaemia is uncertain. Longer regimens may be necessaryMalaria Journal 2009, 8:253 http://www.malariajournal.com/content/8/1/253
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A patient with fatal hyperparasitaemic falciparum malaria
usually dies quickly and is, therefore, unlikely to transmit
resistant parasites. The severely ill patient who survives
will probably receive parenteral treatment, followed by a
full course of oral treatment (now usually an ACT). This
longer course of treatment will increase the chance of
cure. The patient with "uncomplicated hyperparasitae-
mia" (i.e. with no evident clinical signs of severe malaria)
who receives anti-malarial treatment as an outpatient,
therefore, provides the greatest risk of selecting de-novo
resistance as such patients usually receive no special atten-
tion and no special treatment. Identifying such patients
and ensuring they receive adequate treatment would be
expected to reduce the emergence of drug resistance.
Selecting artemisinin resistance
Artemisinins provide low resistance selection probabili-
ties because they are eliminated very rapidly with a half-
life of one hour or less. Thus there is almost no exposure
to residual concentrations in the asexual cycle after the
drug was taken. This creates a unique situation with regard
to anti-malarial resistance selection. All other anti-malari-
als have some effects in more than one asexual cycle. In
order for the artemisinin resistant parasites to survive and
transmit the numbers of sensitive parasites must be
reduced to less than ten times the number of resistant par-
asites. As the modal number of de-novo resistant parasites
at initial drug exposure is one, this means reducing the
number of sensitive parasites to <10. As a symptomatic
infection always has >107 parasites, and as even the most
artemisinin resistant parasites in the world are still killed
by therapeutic levels of the drugs (with PRRs >102), a sin-
gle therapeutic dose of artemisinin (e.g. 4 mg/kg artesu-
nate or artemether) cannot select for resistance, except in
the unusual event described previously that relatively
large numbers of de-novo artemisinin resistant parasites
are present already because they arose at an earlier cell
division [28,29].
Single dose exposure to therapeutic concentrations
If in uncomplicated malaria an adult with a low level
infection of 108 parasites self-treats with a single treatment
dose of artemisinin, then there will be 108 × 10-4 = 104 par-
asites present in the next cycle one to two days later (in
which there is no drug exposure). Even with no fitness dis-
advantage, there would need to be approximately
103resistant parasites at this stage to transmit resistance
(i.e. to comprise 10% of the subsequent gametocytes) as
both resistant and sensitive parasites would then grow
together at the same rate (assuming no second cycle effect
and equal fitness) (Figure 7). If the first level of artemisi-
nin resistance is a 99% reduction in killing efficacy (i.e.
PRRs reducing from 104 to 102 per cycle), then there
would need to have been 105 resistant parasites present in
the previous cycle to generate 103 resistant parasites in the
first post exposure cycle. At multiplication rates of 10 per
cycle it is not possible to generate 105resistant parasites
from de-novo resistance emergence in the blood stage par-
asites. This can result only from de-novo emergence dur-
ing liver stage development - an extremely rare event [6].
Only when total numbers of parasites in the body exceed
109 can this arise from a mitotic event in the blood stage
parasites. For transmission of resistance, the final number
of resistant gametocytes must eventually both exceed 107
and comprise ≥ 10% of the total gametocytes.
Assuming that one parasite initially is resistant then after
s  generations (binary divisions), there are 2s parasites.
Each asexual cycle usually comprises five sets of divisions
(from equation 3). If the PRR following artemisinin expo-
sure is 10,000 and resistance reduces this by a factor b then
after exposure to artemisinin there are 2s (b/10,000) resist-
ant parasites
If the total number of (sensitive) parasites at the time
when resistance first arises is C, then the corresponding
number of sensitive parasites after a single artemisinin
exposure is Cs (1/10,000) sensitive parasites
The minimum conditions for transmission (assuming no
fitness disadvantage) are therefore
2 10 000 2 1 10 000 0 1
ss b (/ , ) / (/ , ) . C×= (1)
Single dose exposure to an artemisinin (arrow) results in a  reduction in the number of sensitive parasites by a factor  (the PRR) of 10,000 fold Figure 7
Single dose exposure to an artemisinin (arrow) 
results in a reduction in the number of sensitive para-
sites by a factor (the PRR) of 10,000 fold. But this is not 
enough to give a de-novo resistant parasites (red line) any 
chance of generating sufficient gametocytes for transmission 
as the sensitive sibling parasites (green lines) remain well 
ahead in the "race" to transmit.
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Likely values for b initially are less than 100, which sug-
gests that artemisinin resistance could spread only in
those rare instances in which resistance arose de-novo
within the first 1,000 mitotic divisions of the liver stage
development. Thus if 108  parasites are the minimum
required to generate a transmissible density of gameto-
cytes, only one of every 100,000 to 1,000,000 infections
in which this level of artemisinin resistance arose de-
novo, and were exposed to a single therapeutic dose of
drug, could generate transmissible resistance. This pre-
sumably explains in part the rarity of de-novo artemisinin
resistance emergence.
Single exposure to sub-therapeutic concentrations
Sub-therapeutic concentrations provide the opportunity
for survival of much greater numbers of both sensitive and
resistant parasites. But transmission of artemisinin resist-
ance would require suppression of the sensitive parasites
through repeated administration of artemisinin. The
resistance risk for a single oral or rectal administration is
therefore extremely low. Occasionally patients will take
artemisinin or its derivatives for fever, which is not
malaria, but by chance at the time of taking the drug
merozoites are emerging from the liver. Up to 100,000
parasites may emerge and be exposed to artemisinin con-
centrations, but it is unlikely each hepatic schizont would
mature at exactly the same time, and so the concentrations
which each schizonts' progeny are exposed to will differ
widely. This reduces the probability of selection by
increasing the chance that some parasites will enter the
blood after artemisinin concentrations have declined
below therapeutic levels. In the example given above,
where artemisinin resistance reduces PRRs 100 fold (from
10,000 to 100), the probability of resistance emergence
exceeds 0.5 only if the following criteria are met:
1.) Hepatic schizont-derived merozoites (i.e. the first
blood stage cycle) are exposed to drug concentrations
in the window of selection (synchronous schizogony).
2.) The number of artemisinin resistant parasites
exceeds 50. If each mature hepatic schizont has 30,000
merozoites (215) then approximately 10% of all de-
novo events per schizont would produce more than 50
parasites.
3.) The total number of blood stage parasites exposed
to the drug is less than 100,000.
Multiple exposure to sub-therapeutic concentrations
In the case of artemisinins either systematic underdosing,
intermittent self-medication with monotherapies, use of a
sub-standard drug, or repeated administration of a rectal
formulation without follow-up treatment provide the
most likely contemporary scenarios for the de-novo emer-
gence of resistance. This is because of the very low proba-
bilities described above for resistance to emerge in a single
in-vivo "selective sweep". Unfortunately the biological,
pharmacological, operational, and behavioural factors
which predispose to the first selection also predispose to
the second and subsequent rounds of selection. A high
parasitaemia provides an increased risk of recrudescence,
and this predisposes to a second recrudescence even with
observed treatment. Underdosing because of incorrect
dose recommendations, poor adherence, or sub-standard
drugs is likely to be repeated
Implications
1. Inadequate dosing of uncomplicated hyperparasi-
taemia provides the most likely scenario for the de-
novo emergence and selection of resistance.
2. Artemisinin resistance is very unlikely to be selected
by a single exposure. Repeated inadequate dosing is
required for selection and spread of artemisinin resist-
ance.
Discussion
Proving the exact individual origins of anti-malarial drug
resistance in malaria endemic areas is probably impossi-
ble. To examine likely scenarios and guide prevention
strategies induction from experimental observations and
biological understanding is, therefore, combined with
predictive mathematical modelling. Experimental evi-
dence in laboratory animals and humans suggests that use
of inadequate anti-malarial treatment doses, particularly
in patients with hyperparasitaemia, may be an important
source of de-novo resistance. It is both hyperparasitaemia
itself (reflecting an unusually large number of parasites
within a single host), and the host and parasite factors
that gave rise to that hyperparasitaemia, which make it
such a potentially dangerous source of anti-malarial drug
resistance. These factors together increase the chance that
a de-novo resistant parasite will emerge, and that its prog-
eny will survive, that the infection will recrudesce, and
that resistance bearing gametes will be transmitted.
Stable resistance can arise whenever there is nuclear divi-
sion, so it may arise in patients with lower parasite bur-
dens, as in uncontrolled self-medication, or from the
exposure of the relatively small numbers of parasites
emerging following hepatic schizogony. The dynamics of
resistance emergence in low parasite biomass infections
are generally similar to that in hyperparasitaemia but,
even though an individual parasite's chance of survival
may be higher, parasite numbers are orders of magnitude
lower. Furthermore, the per-patient probability of an
or   C b = 01 . (2)Malaria Journal 2009, 8:253 http://www.malariajournal.com/content/8/1/253
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effective host response is greater in low biomass infections
(in that hyperparasitaemia reflects an unusually poor host
response and or an unusually favourable host for that par-
ticular parasite). Asymptomatic parasitaemia reflects an
effective density controlling host response, and as a con-
sequence a low individual probability that any newly
emergent resistant parasites could generate transmissible
gametocyte densities, even if anti-malarial treatment was
taken for an incidental fever. An adult with 10% parasitae-
mia contains approximately the same number of parasites
as 10,000 people with aymptomatic parasitaemia. Low
parasite biomass infections are therefore an unlikely
source of de-novo resistance.
The importance of residual drug levels from previous anti-
malarial treatments exposing newly acquired infections to
sub-therapeutic selective drug concentrations has been
much debated as a possible source of resistance [43].
Slowly eliminated, "long half-life" anti-malarials have
been considered particularly vulnerable because they
present a gradient of concentrations over an extended
time period, and therefore a protracted selection opportu-
nity [34]. This is very important as a selective force in the
spread of resistance, but there are several reasons why this
is not an important determinant of de-novo selection. The
first is numerical. The numbers of parasites emerging from
the liver (circa 10,000 to 100,000), and thus the number
of mitoses which could give rise to a resistant parasite, are
over one thousand times lower than in symptomatic
malaria, and approximately one hundred million fold
lower than in a hyperparasitaemic patient [3]. The second
factor is "immunity". In high transmission settings people
are bitten frequently and also take large quantities of anti-
malarial drugs so new infections will commonly "see"
sub-therapeutic levels of anti-malarial drugs. This pro-
vides a de-novo selection opportunity, but survival prob-
abilities for the newly emergent resistant parasite's
progeny are low. They must evade the primed host
defences and outcompete the usually much larger num-
bers of sensitive parasites from the same infection and
others subsequently acquired in the race to produce game-
tocytes. A single resistant parasite's progeny would be
expected to take 8-20 days longer than its 104 to 105 drug
sensitive siblings to generate transmissible gametocyte
densities with unrestricted multiplication. Most acquired
infections in high transmission settings do not generate
transmissible gametocyte densities because of effective
host defence, so the chances of a de-novo resistant para-
site avoiding host defence mechanisms for an additional
one to three weeks are likely to be very low. For artemisi-
nin and its derivatives, there is usually no possibility of
selecting resistance in liver-emergent blood stage parasites
because the drugs are rapidly eliminated from the body
and because of competition from residual drug sensitive
sibling parasites [28]. A third factor in areas of stable
malaria transmission, which may be relevant to some
resistance mechanisms, is that multiplicity of infection
increases the chance of recombination breakdown of mul-
tigenic resistance.
To illustrate further the numerical differences between
hyperparasitaemia and exposure of newly acquired infec-
tions to residual drug levels, an area where each person
receives on average 10 infectious bites each year (EIR 10)
can be considered. It would take one million people ten
years to accumulate the same number of hepatic emergent
parasites (and thus mitotic events) as in one hyperparasi-
taemic individual. Each of these newly emergent infec-
tions offers a low individual probability of surviving to
transmit, and an even lower probability that a de-novo
resistant parasite within the infection could multiply
enough to generate transmissible gametocyte densities. In
contrast, if the single hyperparasitaemic individual
receives inadequate treatment, recrudescence (and thus an
opportunity for selection) is almost inevitable if the
patient survives. The odds of resistance generation are
therefore heavily stacked towards the hyperparasitaemic
patient. Even so the individual probabilities of a resistant
parasite surviving and its progeny being transmitted sub-
sequently are very low unless either there are large num-
bers of resistant parasites (having emerged earlier in
development) (Figure 3), or the new resistance mecha-
nism allows survival in the presence of therapeutic drug
concentrations (high grade resistance).
Previous assessments of resistance have tended either to
consider resistance as a binary (fully resistant/fully sensi-
tive) or ternary (resistant, tolerant, sensitive) process, and
then mainly in the context of resistance spread [44]. The
degree of resistance conferred by the genetic event is criti-
cal in determining the probability of de-novo selection.
Selection of low levels of resistance usually requires mul-
tiple recrudescences before the resistant parasites predom-
inate and can transmit. Unfortunately multiple
recrudescences are common, particularly in low transmis-
sion settings. Once one recrudescence has occurred then
for one or more reasons (adherence, drug quality, phar-
macokinetics, immunity) the host- parasite combination
is unusually favourable for that particular infection.
Molecular epidemiological studies have provided impor-
tant information on the relative importance of de-novo
emergence and spread in the global increase in anti-
malarial drug resistance. It is now evident that spread of
resistance is more important than originally thought, and
that the predominant anti-malarial drug resistance geno-
types derive mainly from relatively few de-novo events.
Despite extensive use of sulphadoxine-pyrimethamine in
high transmission areas of Africa over the past two dec-
ades, and prior use of pyrimethamine alone, these epide-Malaria Journal 2009, 8:253 http://www.malariajournal.com/content/8/1/253
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miological studies indicate that the high level resistance
that has spread across Eastern and Central Africa arose in
Asia [45]. The spread of chloroquine resistance preceded
it along the same route. Most evidence points to low trans-
mission areas as the main source of resistance. In low
transmission settings where individual parasites have a
better chance of surviving in the largely non-immune
human hosts, treatment is used less frequently. As a result,
the probability that liver-emergent parasites would
encounter residual sub-therapeutic anti-malarial concen-
trations from a previous drug administration is reduced.
Even if they do, and are not recognized initially by the
host-immune response, any resistant mutant arising must
outcompete its majority drug- sensitive siblings in the race
to produce gametocytes or fail any subsequent treatment.
The "advantage" that a primary infection has over a recru-
descent infection of not having provoked a specific
immune response is offset by all these other factors.
The importance of correct anti-malarial dosing in the pre-
vention of resistance has not received sufficient attention.
Unfortunately, systematic underdosing of those patients
with the most parasites and the least immunity (children,
pregnant women, hyperparasitaemics) has been com-
mon, as anti-malarial dose regimens have been extrapo-
lated from studies in adults and have often recommended
doses which are too low [36]. Initial dose recommenda-
tions for sulphadoxine-pyrimethamine in children and
for mefloquine were inadequate, and may well have
engendered resistance [36,46,47]. Initial dose regimens of
artemether-lumefantrine were also too low. Pregnant
women may be an important source of resistance. They
may have a considerable burden of parasites in the pla-
centa, have poor host-defence against malaria and usually
have lower anti-malarial drug levels than non-pregnant
adults. Some patients have unusual pharmacokinetics
resulting in low drug levels. This is a host property so on
retreatment they will usually have low levels again, con-
tributing to the risk of recrudescence and resistance selec-
tion. Anti-malarial dose regimens should be designed to
achieve effective drug concentration profiles in nearly all
patients. Many do not (Table 2).
Hyperparasitaemia is an important source of resistance
but it is often not recognized. Most patients with falci-
parum malaria do not obtain a diagnosis, and of those
who do get parasitological assessment, few have accurate
counts made. Rapid diagnostic tests are being introduced
but are used qualitatively not quantitatively. It was once
recommended that children with a fever in high transmis-
sion areas should receive anti-malarial drugs without
making a diagnosis. This position is now changing. If
patients with hyperparasitaemia could be identified, and
were given an extended course of curative treatment, the
emergence of anti-malarial drug resistance might be
delayed. These observations emphasize the importance of
ensuring that anti-malarial drug quality is good, that
monotherapies are never used, that doses are optimized
on the basis of pharmacodynamic and pharmacokinetic
assessment in the target populations, and that patients
with heavy parasite burdens receive adequate treatment to
prevent recrudescence.
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